Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Withdrawn 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 1Endocrine 1CNS 1

Conditions

Neuroendocrine Tumors 40Gastro-enteropancreatic neuroendocrine tumor 8Paraganglioma 6Meningioma 6Pheochromocytoma 5Carcinoma, Neuroendocrine 4Neuroblastoma 3Carcinoid Tumor 3Adenoma, Islet Cell 3Prostatic Neoplasms 2Pancreatic Neoplasms 2Neoplasms, Germ Cell and Embryonal 2Neoplasms 2Medulloblastoma 2Glioma 2Glioblastoma 2Ependymoma 2Carcinoma, Merkel Cell 2Carcinoma, Medullary 2Stomach Neoplasms 1Somatostatinoma 1Somatostatin Receptor-positive Neuroendocrine Tumor 1Somatostatin Receptor-positive GEP-NET 1Small Cell Lung Carcinoma 1Serotonin Syndrome 1Sarcoma, Synovial 1Recurrence 1Pituitary Neoplasms 1Parathyroid Neoplasms 1Pancreatic Diseases 1

Interventions

vandetanib 14cabozantinib 9selpercatinib 6Sorafenib 5Everolimus 5pralsetinib 3Magnetic Resonance Spectroscopy 3Capecitabine 3sargramostim 2lutetium Lu 177 dotatate 2lenvatinib 2Trastuzumab 2Thyroidectomy 2Temozolomide 2Sunitinib 2Specimen Handling 2Octreotide 2High-Energy Shock Waves 2Gefitinib 2Doxorubicin 2yeast-CEA vaccine 1veliparib 1vatalanib 1tumor necrosis factor-alpha, CNGRC fusion protein, human 1tipifarnib 1temsirolimus 1tanespimycin 1sacubitril and valsartan sodium hydrate drug combination 1rovalpituzumab tesirine 1ponatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Carcinoma, Medullary × lutetium Lu 177 dotatate × Clear all
NCT06121271 2023-12-07

Trial of Lu-177 DOTATATE (Lutathera®) in Unlicensed Indications

University College, London

Phase 2 Not yet recruiting
110 enrolled

Carcinoma, Medullary

NCT04106843 2020-09-07

Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers

M.D. Anderson Cancer Center

Phase 2 Withdrawn
CNSEndocrineHead & Neck

Paraganglioma, Parathyroid Neoplasms, Pheochromocytoma, Pituitary Neoplasms, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon ⚡